{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:56:34Z","timestamp":1774526194414,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"DOI":"10.7759\/cureus.105881","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:54:37Z","timestamp":1774522477000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Pre-exposure Prophylaxis (PrEP) in the Prevention of Human Immunodeficiency Virus (HIV): A Systematic Review of Randomized Controlled Trials With Narrative Synthesis"],"prefix":"10.7759","author":[{"given":"Bhavesh","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ojasvi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"2024 Global AIDS Report - The Urgency of Now: AIDS at a Crossroads","year":"2024","unstructured":"2024 Global AIDS Report - The Urgency of Now. AIDS at a Crossroads. Joint United Nations Programme on HIV\/AIDS, Geneva; 2024."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano R","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al.. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012, 380:2095-128. 10.1016\/S0140-6736(12)61728-0","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017","volume":"6","year":"2019","unstructured":"Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories. a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019, 6:e831-59. 10.1016\/S2352-3018(19)30196-1","journal-title":"Lancet HIV"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31070-5","article-title":"Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission","volume":"392","author":"Bekker LG","year":"2018","unstructured":"Bekker LG, Alleyne G, Baral S, et al.. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018, 392:312-58. 10.1016\/S0140-6736(18)31070-5","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant RM","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al.. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010, 363:2587-99. 10.1056\/NEJMoa1011205","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya K","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al.. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013, 381:2083-90. 10.1016\/S0140-6736(13)61127-7","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten JM","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al.. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012, 367:399-410. 10.1056\/NEJMoa1108524","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz RJ","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, et al.. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021, 385:595-608. 10.1056\/NEJMoa2101016","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe S","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, et al.. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022, 399:1779-89. 10.1016\/S0140-6736(22)00538-4","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks SG","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013, 382:1525-33. 10.1016\/S0140-6736(13)61809-7","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.85940","article-title":"Zotero: a bibliographic assistant to researcher","volume":"2","author":"Ahmed KK","year":"2011","unstructured":"Ahmed KK, Al Dhubaib BE. Zotero: a bibliographic assistant to researcher. J Pharmacol Pharmacother. 2011, 2:303-5. 10.4103\/0976-500X.85940","journal-title":"J Pharmacol Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo JM","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al.. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015, 372:509-18. 10.1056\/NEJMoa1402269","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme L","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al.. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012, 367:411-22. 10.1056\/NEJMoa1202614","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack S","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, et al.. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016, 387:53-60. 10.1016\/S0140-6736(15)00056-2","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina JM","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, et al.. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015, 373:2237-46. 10.1056\/NEJMoa1506273","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"Thigpen MC","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, et al.. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012, 367:423-34. 10.1056\/NEJMoa1110711","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu O","year":"2021","unstructured":"Ogbuagu O, Ruane PJ, Podzamczer D, et al.. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021, 8:e397-407. 10.1016\/S2352-3018(21)00071-0","journal-title":"Lancet HIV"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13492","article-title":"Barriers and facilitators to HIV pre-exposure prophylaxis (PrEP) in specialist sexual health services in the United Kingdom: a systematic review using the PrEP Care Continuum","volume":"24","author":"Coukan F","year":"2023","unstructured":"Coukan F, Murray KK, Papageorgiou V, Lound A, Saunders J, Atchison C, Ward H. Barriers and facilitators to HIV pre-exposure prophylaxis (PrEP) in specialist sexual health services in the United Kingdom: a systematic review using the PrEP Care Continuum. HIV Med. 2023, 24:893-913. 10.1111\/hiv.13492","journal-title":"HIV Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7347a3","article-title":"Progress toward UNAIDS global HIV pre-exposure prophylaxis targets: CDC-supported oral pre-exposure prophylaxis - 37 countries, 2017-2023","volume":"73","author":"Peck ME","year":"2024","unstructured":"Peck ME, Davis S, Odoyo-June E, et al.. Progress toward UNAIDS global HIV pre-exposure prophylaxis targets: CDC-supported oral pre-exposure prophylaxis - 37 countries, 2017-2023. MMWR Morb Mortal Wkly Rep. 2024, 73:1082-6. 10.15585\/mmwr.mm7347a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1590\/0034-7167-2021-0963","article-title":"Barriers to pre-exposure prophylaxis (PrEP) use for HIV: an integrative review","volume":"76","author":"Antonini M","year":"2023","unstructured":"Antonini M, Silva IE, Elias HC, Gerin L, Oliveira AC, Reis RK. Barriers to pre-exposure prophylaxis (PrEP) use for HIV: an integrative review. Rev Bras Enferm. 2023, 76:e20210963. 10.1590\/0034-7167-2021-0963","journal-title":"Rev Bras Enferm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473276-effectiveness-of-pre-exposure-prophylaxis-prep-in-the-prevention-of-human-immunodeficiency-virus-hiv-a-systematic-review-of-randomized-controlled-trials-with-narrative-synthesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:54:38Z","timestamp":1774522478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473276-effectiveness-of-pre-exposure-prophylaxis-prep-in-the-prevention-of-human-immunodeficiency-virus-hiv-a-systematic-review-of-randomized-controlled-trials-with-narrative-synthesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.105881","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}